Xspray Pharma AB ((DE:6XP)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Xspray Pharma AB recently completed a clinical study titled An Open-label, Randomized, Four-treatment, Four-period, Four-sequence, Single Dose, Crossover Study to Evaluate the Dose Adjusted Relative Bioavailability of Nilotinib. The study aimed to assess the bioavailability of Nilotinib in healthy adults under fasted conditions, crucial for optimizing dosage forms and enhancing therapeutic efficacy.
Intervention/Treatment: The study tested the bioavailability of two formulations of Nilotinib: Tasigna capsules (200 mg and 400 mg) and XS003 capsules (96 mg and 192 mg). These interventions are designed to evaluate the pharmacokinetic properties and dose proportionality of Nilotinib.
Study Design: This Phase 1 study was interventional, with a randomized, crossover design. It was open-label, meaning no masking was involved, and aimed primarily at treatment evaluation. Participants received single doses of each treatment under fasting conditions.
Study Timeline: The study began on November 15, 2024, and was completed by August 20, 2025. These dates are significant as they mark the period over which data was collected and analyzed, leading to the recent update.
Market Implications: The completion of this study could positively impact Xspray Pharma’s stock performance by demonstrating the potential of their XS003 formulation. This development might influence investor sentiment favorably, especially if the results show improved bioavailability compared to existing treatments. It also positions Xspray Pharma competitively in the pharmaceutical industry.
The study is completed, and further details are available on the ClinicalTrials portal.